Fig. 3.

Ponatinib acts synergistically with fluconazole against azole‐resistant clinical isolates and prevents the emergence of resistance. CCC49 (A–D) and CCC80 (E–H) were subjected to twofold serial dilutions of fluconazole, ponatinib or both in YPD medium. OD₆₀₀ was measured every 15 min at 30°C for 16 h, and FICI was calculated by standard CLSI broth microdilution method (M38‐A).

I. C. albicans (SC5314) cells were inoculated into YPD plates containing indicated dosages of compounds (DMSO, 32 μg ml^‐1 fluconazole, 32 μM ponatinib, combination). The cell growth of resistant strains was observed after 3 days. ****P < 0.0001 vs. DMSO (the one‐way ANOVA and Tukey multiple comparisons).